Please assess the completion status of the following clinical trial:

Trial Title: A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (age ≥ 18 years) subjects with peripheral lung lesions that are \<1.5 cm in size who are planning to undergo percutaneous image guided lung biopsy as part of their routine medical care.~* 2. Ability to understand and willingness to sign Informed Consent Document (ICD)~Exclusion Criteria:~* Age less than 18 years.~* Pregnant or nursing females.~* Known allergy to iodine or intravenous contrast agent.~* Known allergy or anaphylactic reaction to indocyanine green (ICG).~* Patients with renal dysfunction (GFR \<60) or patients on dialysis~* Patients with liver dysfunction: total bilirubin \> 2.5 mg/dl; albumin \< 2.5 mg/dl; alanine aminotransferase (ALT), aspartate aminotransferase (AST) \> 5 times upper limits of normal~* Uncorrectable coagulopathy prohibiting biopsy. (INR \> 1.5 and/ or platelets \< 50,000)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 2 (Type: EXPERIMENTAL): During standard of care lung biopsy, the doctor will use the MIMIG system to help guide the needle for the the lung biopsy.
- Group 3 (Type: EXPERIMENTAL): During standard of care lung biopsy, the doctor will use the MIMIG system to help guide the needle for the lung biopsy. An intravenous (IV) needle placed in the vein to give indocyanine green (IC-Green). Fiber Optic camera will be used to view tissue before biopsy via insertion catheter.
- Group 1 (Type: NO_INTERVENTION): Control Group consists of twelve patients who have undergone biopsy of a peripheral lung lesion by using repetitive CT-guidance. Review of medical records only, no further intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).